Key Developments: Orexigen Therapeutics Inc (OREX.O)

OREX.O on Nasdaq

4.99USD
31 Jul 2014
Price Change (% chg)

$-0.09 (-1.77%)
Prev Close
$5.08
Open
$5.04
Day's High
$5.10
Day's Low
$4.96
Volume
3,326,868
Avg. Vol
3,463,458
52-wk High
$7.84
52-wk Low
$4.59

Search Stocks

Latest Key Developments (Source: Significant Developments)

Orexigen Therapeutics Inc receives three month extension of FDA NB32 review
Wednesday, 11 Jun 2014 06:30am EDT 

Orexigen Therapeutics Inc:Says the United States Food and Drug Administration (FDA) has extended its review of the resubmitted New Drug Application (NDA) for NB32, the company's investigational medication being evaluated for weight loss.The new Prescription Drug User Fee Act (PDUFA) action date has been set for Sept. 11, 2014.The FDA has indicated that the review extension is needed to reach agreement on the post-marketing obligation related to the previously agreed upon evaluation of cardiovascular (CV) outcomes for NB32.  Full Article

Orexigen Therapeutics Inc announces closing of its offering of $115 mln of convertible senior notes
Friday, 6 Dec 2013 10:45am EST 

Orexigen Therapeutics Inc:Says the closing of its offering of $115 mln aggregate principal amount of convertible senior notes due 2020.Says convertible senior notes also includes $15 mln aggregate principal amount of the Notes issued in connection with the exercise by the initial purchasers of their option to purchase additional Notes in full.Says the Notes were offered in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.Says the Notes bear interest semi-annually at a rate of 2.75 percent per year.Says the Notes will mature on Dec. 1, 2020, unless earlier repurchased or converted in accordance with their terms prior to such date.Says it estimates that the net proceeds from the offering will be about $110.5 million after deducting the initial purchasers' discounts and commissions and the estimated offering expenses payable by it.Says the company intends to use the net proceeds from the offering of the Notes for working capital and other general corporate purposes.  Full Article

Orexigen Therapeutics Inc announces offering of $100 mln of convertible senior notes
Monday, 2 Dec 2013 07:00am EST 

Orexigen Therapeutics Inc:Says it intends to offer $100 mln aggregate principal amount of convertible senior notes due 2020.Says it intends to use the net proceeds from the offering of the Notes for working capital and other general corporate purposes.  Full Article

Robbins Arroyo LLP Is Investigating Directors and Officers of Orexigen Therapeutics Inc
Monday, 12 Aug 2013 07:42pm EDT 

Robbins Arroyo LLP is investigating whether certain officers and directors of Orexigen Therapeutics Inc breached their fiduciary duties to shareholders. Orexigen focuses on the development of pharmaceutical product candidates for the treatment of obesity.  Full Article

The Law Firm of Levi & Korsinsky, LLP Launches An Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Directors Of Orexigen Therapeutics Inc
Tuesday, 7 May 2013 11:52am EDT 

Levi & Korsinsky, LLP announced that it is investigating Orexigen Therapeutics Inc and its Board of Directors, in connection with possible claims of breaches of fiduciary duty.  Full Article

Orexigen Therapeutics Inc Prices Public Offering Of Common Stock
Thursday, 25 Oct 2012 09:07am EDT 

Orexigen Therapeutics Inc announced that it has priced an underwritten public offering of 11,000,000 shares of its common stock at a price of $5.50 per share. Net proceeds, after underwriting discounts and commissions and estimated expenses, will be approximately $56.5 million. Orexigen has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of common stock. The offering is expected to close on or about October 30, 2012, subject to satisfaction of customary closing conditions. Credit Suisse Securities (USA) LLC, BofA Merrill Lynch and Leerink Swann LLC are acting as joint book-running managers for the offering.  Full Article

Orexigen Therapeutics Inc Announces Proposed Public Offering Of Common Stock
Wednesday, 24 Oct 2012 04:01pm EDT 

Orexigen Therapeutics Inc announced that it intends to offer shares of its common stock in an underwritten public offering. In connection with this offering, Orexigen expects to grant to the underwriters a 30-day option to purchase additional shares of common stock. All of the shares are being offered by Orexigen. Credit Suisse Securities (USA) LLC, BofA Merrill Lynch and Leerink Swann LLC are acting as joint book-running managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.  Full Article

MARKET PULSE-Bancorp, Biofuel, Boeing, Ocera, Orexigen

NOTE TO SUBSCRIBERS: Reuters is converting some short-form coverage of hot stocks, including Market Pulse, into the new Stocks Buzz product. From June 16, items that were previously published only as a compilation will be published as standalone items featuring the BUZZ tag. They will also be accessible via the STXBZ news code. A collated version will continue to appear on the WATCH/US named-item code under the headline "BUZZ-U.S. stocks on the move".

Search Stocks